Literature DB >> 9365893

HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management.

A N Phillips1, A McLean, M A Johnson, M Tyrer, V Emery, P Griffiths, M Bofill, G Janossy, C Loveday.   

Abstract

Simple models of CD4 lymphocyte interactions with human immunodeficiency virus (HIV) lead to the hypothesis that progression of HIV infection involves an increase in viral replicative capacity, due either to changes in the virus or in the host environment, or both. In order to consider how changes in plasma virus load after transient, potent antiretroviral therapy can be used to test the above hypothesis--a simple mathematical model that encompasses the processes of (1) arrival of new CD4 lymphocytes, (2) death/removal of these cells by HIV-independent mechanisms, (3) infection of susceptible CD4 lymphocytes by HIV, and (4) death/removal of infected cells was investigated. This showed that the in vivo rate of increase in plasma virus load immediately after transient therapy provides a measure of the viral replicative capacity. Thus, the hypothesis that progression of HIV infection involves an increase in viral replicative capacity can be tested by measuring this viral growth rate in patients with high CD4 counts and in patients with low CD4 counts. Studies should thus investigate dynamics of changes in virus levels after stopping antiretroviral therapy and, in particular, measure rates of increase in virus in patients at high and low CD4 counts. In practice, such data may assist in therapeutic management of patients with HIV infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365893

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

Review 1.  Monitoring patients with HIV disease.

Authors:  M Helbert; J Breuer
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

2.  Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection.

Authors:  Christina M R Kitchen; Lilit Yeghiazarian; Rebecca Hoh; Joseph M McCune; Elizabeth Sinclair; Jeffrey N Martin; Steven G Deeks
Journal:  PLoS One       Date:  2011-06-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.